Making Zolbetuximab deliverable in practice: multidisciplinary management of nausea, vomiting, gastritis, and hypoalbuminemia in first-line CLDN18.2-positive, HER2-negative gastric/GEJ adenocarcinoma.

Sagawa T, Nagashima H, Fujikawa K

Open source

DOI
10.1007/s12032-026-03422-3
Published
2026 Sep 25
Container
Medical oncology (Northwood, London, England)
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1007/s12032-026-03422-3,
  title = {Making Zolbetuximab deliverable in practice: multidisciplinary management of nausea, vomiting, gastritis, and hypoalbuminemia in first-line CLDN18.2-positive, HER2-negative gastric/GEJ adenocarcinoma.},
  author = {Sagawa T and Nagashima H and Fujikawa K},
  year = {2026},
  journal = {Medical oncology (Northwood, London, England)},
  doi = {10.1007/s12032-026-03422-3},
  url = {https://doi.org/10.1007/s12032-026-03422-3}
}

RIS

TY  - JOUR
TI  - Making Zolbetuximab deliverable in practice: multidisciplinary management of nausea, vomiting, gastritis, and hypoalbuminemia in first-line CLDN18.2-positive, HER2-negative gastric/GEJ adenocarcinoma.
AU  - Sagawa T
AU  - Nagashima H
AU  - Fujikawa K
PY  - 2026
JO  - Medical oncology (Northwood, London, England)
DO  - 10.1007/s12032-026-03422-3
UR  - https://doi.org/10.1007/s12032-026-03422-3
ER  - 

APA

T, S., H, N., & K, F. (2026). Making Zolbetuximab deliverable in practice: multidisciplinary management of nausea, vomiting, gastritis, and hypoalbuminemia in first-line CLDN18.2-positive, HER2-negative gastric/GEJ adenocarcinoma.. Medical oncology (Northwood, London, England). https://doi.org/10.1007/s12032-026-03422-3

Source records